# Main Categories of Lung Cancer and Their Characteristics

## 1. Non-Small Cell Lung Cancer (NSCLC)
**NSCLC** is the most common form of lung cancer, accounting for **70-80% of all lung cancers**.

### **Subtypes and Characteristics**
| **Subtype**              | **Frequency** | **Histological Features**                                                                                       | **Molecular Features** | **Treatment Options** |
|-------------------------|---------------|-----------------------------------------------------------------------------------------------------------------|------------------------|----------------------|
| **Adenocarcinoma**      | ~40-45%       | Glandular differentiation, peripheral lung location, mucin production.Most frequent, especially in non-smokers. | **EGFR, ALK, KRAS, ROS1, MET, BRAF mutations**; PD-L1 expression | **Targeted therapy, Immunotherapy, Chemotherapy, Surgery (early stage)** |
| **Squamous Cell Carcinoma (SCC)** | ~25-30%       | Centrally located, keratin pearls, intercellular bridges. More common in smokers.                                                      | **TP53, FGFR1, CDKN2A mutations**; Less common EGFR mutations | **Chemotherapy, Immunotherapy (PD-L1 inhibitors), Surgery (early stage)** |
| **Large Cell Carcinoma** | ~5-10%        | Poorly differentiated, lacks glandular/squamous differentiation                                                 | **Rare driver mutations**; May have **PD-L1 expression** | **Immunotherapy, Chemotherapy, Surgery if resectable** |

### **Molecular Features & Targeted Therapies in NSCLC**
| **Molecular Target**                         | **Mutation Type** | **Associated Subtype** | **Targeted Therapy**                                                                              |
|----------------------------------------------|------------------|------------------------|---------------------------------------------------------------------------------------------------|
| **EGFR (Epidermal Growth Factor Receptor)** <br/>(10-20%)  | Activating mutations (e.g., L858R, Exon 19 deletions) | Adenocarcinoma, Non-smokers | Targeted by tyrosine kinase inhibitors (TKIs)<br/>**Osimertinib (EGFR-TKI), Erlotinib, Afatinib** |
| **ALK (Anaplastic Lymphoma Kinase)**         | ALK rearrangements (e.g., EML4-ALK) | Adenocarcinoma, Younger patients | Fusion-targeted drugs<br/>**Alectinib, Lorlatinib, Crizotinib**                                   |
| **KRAS**<br/>(~35-40%)                       | KRAS G12C mutations <br/>(common in smokers, ~15-20% prevalence).| Adenocarcinoma, Smokers<br/>Environmental exposure-related mutation. | KRAS-targeted therapies (e.g., Sotorasib) are emerging.<br/>**Sotorasib (KRAS G12C inhibitor)**                                                               |
| **ROS1**                                     | ROS1 rearrangements | Adenocarcinoma, Non-smokers | **Crizotinib, Lorlatinib**                                                                        |
| **BRAF**                                     | BRAF V600E mutation | Adenocarcinoma | **Dabrafenib + Trametinib**                                                                       |
| **MET**                                      | MET exon 14 skipping mutation | Adenocarcinoma | **Tepotinib, Capmatinib**                                                                         |
| **PD-L1**                                    | High expression (>50%) | All NSCLC subtypes | **Pembrolizumab, Nivolumab (Checkpoint inhibitors)**                                              |

### **Treatment Approach for NSCLC**
- **Early-stage (I–IIIA):** Surgery ± Adjuvant chemotherapy
- **Locally advanced (IIIB):** Chemoradiation ± Immunotherapy
- **Metastatic (Stage IV):**  
  - **Targeted therapy** (if driver mutation present)
  - **Immunotherapy (PD-1/PD-L1 inhibitors)**
  - **Chemotherapy** (platinum-based doublet)

---

## 2. Small Cell Lung Cancer (SCLC)
**SCLC** accounts for **~15% of lung cancers** and is highly aggressive.

### **Key Characteristics**
| **Feature**          | **Description** |
|----------------------|----------------|
| **Histology**        | Small, round blue cells, neuroendocrine differentiation, high mitotic rate |
| **Location**        | Centrally located (near bronchi) |
| **Molecular Features** | **TP53, RB1 mutations**, MYC amplifications, DLL3 overexpression |
| **Growth Pattern**   | Rapid progression, early metastasis |
| **Paraneoplastic Syndromes** | SIADH (hyponatremia), Cushing's syndrome (ACTH secretion), Lambert-Eaton syndrome |

### **Treatment Approach for SCLC**
- **Limited stage (Confined to one lung field)**
  - **First-line:** **Concurrent Chemoradiation** (Cisplatin/Etoposide + Radiation)
  - **Prophylactic Cranial Irradiation (PCI)** to prevent brain metastases
- **Extensive stage (Metastatic)**
  - **First-line:** **Immunotherapy + Chemotherapy** (Atezolizumab/Durvalumab + Platinum/Etoposide)
  - **Second-line:** Lurbinectedin (for relapsed disease)
  - **Limited options for targeted therapy** due to lack of actionable mutations.

---

## 3. Summary of Molecular Characteristics & Treatment Options
| **Cancer Type** | **Key Molecular Features** | **Targeted Therapy?** | **Immunotherapy Response?** |
|---------------|--------------------------|------------------|------------------|
| **NSCLC - Adenocarcinoma** | EGFR, ALK, KRAS, ROS1, BRAF, MET mutations | Yes | Yes (PD-L1 high) |
| **NSCLC - Squamous Cell** | TP53, FGFR1, CDKN2A | No (rare) | Yes |
| **NSCLC - Large Cell** | PD-L1 expression in some cases | Rare | Yes |
| **SCLC** | TP53, RB1 loss, MYC amplification | No | Moderate |

---

## 4. Key Takeaways
- **NSCLC (~85%)** is the most common lung cancer type and has multiple **targeted therapy options** based on genetic profiling.
- **SCLC (~15%)** is highly aggressive but lacks effective **targeted therapies**.
- **PD-L1 testing and molecular profiling** are **critical for treatment selection**.
- **Immunotherapy plays a major role in both NSCLC and SCLC**.


